DDO-2093

• Description :

  DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex[1].

• CAS Number :

  [2250024-74-7]

• UNSPSC :

  12352005

• Target :

  WDR5

• Type :

  Reference compound

• Related Pathways :

  Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ddo-2093.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CN(C2=CC=C(N3CCN(C)CC3)C(NC(C4=CC(N)=C(F)C(C)=C4Cl)=O)=C2)N=N1)NCCCN5CCOCC5

• Molecular Formula :

  C29H37ClFN9O3

• Molecular Weight :

  614.11

• References & Citations :

  [1]Chen W, et al. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity [published online ahead of print, 2021 Jun 28]. Eur J Med Chem. 2021;223:113677.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported